For Health Care Professionals Outside the US
  • US Residents
  • REVOLADE Product Characteristics
  • Safety Information
REVOLADE® (eltrombopag)
  • Efficacy
    • ITP
      • Adult ITP
      • Paediatric ITP
    • SAA
    • Chronic HCVaT
      • Platelet response
      • Sustained virologic response
    • Study Designs
      • ITP
      • SAA
      • Chronic HCVaT
  • Safety
    • ITP
      • Most common AEs
      • VTE
      • Bone marrow fibrosis
    • SAA
    • HCVaT
  • Patient Experience
    • Patient Preferences
      • Once-daily Oral Therapy
      • REVOLADE to Other TPO-RAs
    • Why choose REVOLADE
      • Corticosteroids
      • Rituximab
      • Splenectomy
      • Other TPO-RAs
  • MOA
    • Complements Endogenous TPO
    • ITP
    • SAA
    • Immunomodulatory Response
  • Dosing & Administration
    • Dosing and administration
      • Dosing
      • Dietary guidelines
    • Dosing flexibility

REVOLADE Enables Treatment by
The Route Patients Prefer

Patients prefer once-daily oral therapy vs injections1

Most patients prefer once-daily oral therapy over injectables or twice-daily oral therapy Most patients prefer once-daily oral therapy over injectables or twice-daily oral therapy
  • These results are based on the responses of 1,491 patients who participated in a patient and physician survey on immune thrombocytopenia (ITP) conducted in 13 countries1
Patient Preference for Oral Therapy Was
Confirmed in International Studies2-4
  • These 3 studies assessed outcomes before and after patients switched (N=178) between the thrombopoietin receptor agonists (TPO-RAs) romiplostim and REVOLADE
    • Also evaluated were the reasons patients were switched from one therapy to another2-4
In a patient survey, 100% of patients who chose to switch their TPO-RA switched to REVOLADE In a patient survey, 100% of patients who chose to switch their TPO-RA switched to REVOLADE
  • Additionally, of the patients who switched therapy due to experiencing platelet fluctuations, 92% (23/25) switched from romiplostim to REVOLADE2-4

References:

1. Data on file. 2. Carpenedo M, Cantoni S, Mazzucconi MG, et al. Sequential use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: a retrospective collaborative survey from Italian hematology centers. Poster presented at: The 22nd European Hematology Association Congress; June 24, 2017; Madrid, Spain. Abstract P722. 3. Lakhwani S, Perera M, Fernández-Fuertes F, et al. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: a retrospective collaborative survey involving 4 Spanish centres. Eur J Haematol. 2017;99(4):372-377. 4. Khellaf M, Viallard J-F, Hamidou M, et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica. 2013;98(6):881-887.

  • Privacy
  • Cookie Preferences
  • Site Map
  • Contact Us
  • Summary of Product Characteristics
  • Safety Information
Novartis
© 2019 Novartis | Use of this website is subject to our Terms of Use
Disclaimer: This is an international website for REVOLADE® (eltrombopag) and is intended for health care professionals outside the US. If you are a US resident, please click on the US Residents links at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
This is an international site for REVOLADE® (eltrombopag) and is intended for health care professionals outside the US.
REVOLADE® (eltrombopag) clinical information
  • Health Care Professionals
  • Patients
I am a Health Care Professional outside the US
Enter site

The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country. Please contact your local Novartis representative for local prescribing information via https://www.novartis.com/our-company/contact-us.

IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC)

US HCPs & Other
Country-Specific Websites

At right is a list of the countries that host a REVOLADE website based on local label and in a local language. They are intended for health care professionals (HCPs) only. If you are an HCP from one of the countries listed at right, click on your country’s link to be redirected to your country’s REVOLADE website.

Choose Country
United States
  • I am a Patient inside the US
  • I am a Patient outside the US